Press Release

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ:VCYT) today announced that data from a prospective clinical utility study demonstrating the ability of the Percepta^® Bronchial Genomic Classifier to safely reduce unnecessary invasive procedures in lung cancer screening and diagnosis will be presented at CHEST 2017, the annual meeting of the American College of Chest Physicians. The study data will be shared in an oral presentation at the meeting, being held October 28 to November 1 in Toronto, Canada.

"As lung cancer screening expands in the United States, a common concern among physicians is that many patients with suspicious lung nodules will undergo unnecessary invasive procedures to rule out cancer," said Bonnie Anderson, Veracyte's chairman and chief executive officer. "The findings to be shared at the CHEST meeting demonstrate that the Percepta classifier can reduce unnecessary diagnostic surgeries when suspicious nodules are found on CT scans, improving patient care and reducing healthcare costs."

Data from the following study will be shared in an oral presentation at the meeting:

The clinical utility data to be presented at CHEST 2017 adds to the library of clinical evidence supporting the Percepta classifier, which includes positive clinical validation data published in The New England Journal of Medicine. It also follows the recent positive Medicare coverage policy for the test by the Centers for Medicare & Medicaid Services' MolDx program.

About Percepta

The Percepta Bronchial Genomic Classifier is used to reduce unnecessary surgeries and costs in lung cancer screening and diagnosis. The 23-gene classifier effectively identifies patients who are at low risk of lung cancer following an inconclusive result from bronchoscopy - a minimally invasive procedure that is commonly used to evaluate lung nodules. This can enable these patients to be monitored with computed tomography (CT) scans in lieu of invasive, risky and costly diagnostic procedures that frequently prove to be unnecessary. The classifier's performance has been verified in multiple, rigorous clinical studies, including clinical validation data published in The New England Journal of Medicine. The Percepta classifier is broadly available to patients within the Medicare system. The Percepta classifier uses proprietary "field of injury" technology to detect molecular changes in the lining of the respiratory tract of current or former smokers, which are indicative of cancer or cancer-related changes in the lung.

About Veracyte

Veracyte (NASDAQ:VCYT) is a leading genomic diagnostics company that is providing trustworthy and actionable answers that fundamentally improve patient care when current diagnostic tests are uncertain. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, our beliefs with respect to the benefits of Percepta, including its ability to reduce unnecessary diagnostic surgeries in certain circumstances, improving patient care and reducing healthcare costs, and the applicability of clinical results to actual outcomes. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: demand for our tests, the applicability of clinical results to actual outcomes; laws and regulations applicable to our business, including potential regulation by the Food and Drug Administration or other regulatory bodies; the size of the market opportunity for our products; our ability to successfully achieve and maintain adoption of and reimbursement for our products; the amount by which use of our products are able to reduce unnecessary surgeries, improve patient care, and reduce healthcare costs; the occurrence and outcomes of clinical studies; the timing and publication of clinical study results; and other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements.

Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171019005490/en/

Veracyte, Inc.
Media:
Tracy Morris, 650-380-4413
tracy.morris@veracyte.com
or
Investors:
Jackie Cossmon, 650-243-6371
jackie@veracyte.com

Source: Veracyte, Inc.

News Provided by Acquire Media